Morris H G, Jorgensen J R, Elrick H, Goldsmith R E
J Clin Invest. 1968 Mar;47(3):436-51. doi: 10.1172/JCI105740.
The effects of administered human growth hormone (HGH) were evaluated in dwarfed, prepubertal children who were receiving long-term corticosteroid therapy for a chronic disease. During 11 complete metabolic balance studies, the eight corticosteroid-treated children demonstrated impaired response to large doses of HGH with minimal nitrogen and no phosphorus retention. In contrast, two hypopituitary subjects and two asthmatic children not receiving corticosteroid responded to the same preparations of HGH with nitrogen, potassium, and phosphorus retention. Six corticosteroid-treated children were given large doses of HGH (40-120 mg/wk for 4 to 8 months and showed no improvement in their retarded rate of growth, whereas the hypopituitary subjects showed accelerated growth during administration of 10-15 mg of HGH/wk. It is concluded that dwarfism in steroid-treated children results from corticosteroid-induced antagonism of the effects of HGH at the peripheral tissue level.
对因慢性疾病接受长期皮质类固醇治疗的青春期前侏儒儿童给予人生长激素（HGH）进行效果评估。在11项完整的代谢平衡研究中，8名接受皮质类固醇治疗的儿童对大剂量HGH反应受损，氮潴留极少且无磷潴留。相比之下，2名垂体功能减退受试者和2名未接受皮质类固醇治疗的哮喘儿童对相同制剂的HGH有氮、钾和磷潴留反应。6名接受皮质类固醇治疗的儿童接受了大剂量HGH（40 - 120毫克/周，持续4至8个月），但其生长迟缓率并未改善，而垂体功能减退受试者在每周给予10 - 15毫克HGH时生长加速。结论是，接受类固醇治疗儿童的侏儒症是由皮质类固醇在外周组织水平诱导的对HGH作用的拮抗所致。
